The versatile nature of Kinesyx™ technology allows for the coating of various drugs directly onto the surface of a medical device and the tailoring of the drug release profile depending on therapeutic requirements. This can range from a 30 day release from a metallic stent to a 60 second release from a nylon balloon.
IBI’s current focus is the development of a drug coated balloon (DCB) for peripheral vascular disease in partnership with Qualimed, a German manufacturer of medical devices.
The product under development has a strong safety profile, competitive tissue uptake, consistent coating deposition, low loss in transit, flexibility/pliability and produces minimal particulates. The IQ-1 DCB is expected to begin FIM trials and application for CE Mark in 2017.
Drug Coated Balloon for coronary and peripheral applications →